This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Nov;68(5):802-4.

doi: 10.1016/j.eururo.2015.04.019. Epub 2015 Apr 24.

Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?

Laurence Albiges¹, Yohann Loriot², Christophe Massard¹, Karim Fizazi¹

Affiliations

Affiliations

¹ Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
² Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.

PMID: 25922192
DOI: 10.1016/j.eururo.2015.04.019

Editorial

Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?

Laurence Albiges et al. Eur Urol. 2015 Nov.

. 2015 Nov;68(5):802-4.

doi: 10.1016/j.eururo.2015.04.019. Epub 2015 Apr 24.

Authors

Laurence Albiges¹, Yohann Loriot², Christophe Massard¹, Karim Fizazi¹

Affiliations

¹ Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
² Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.

PMID: 25922192
DOI: 10.1016/j.eururo.2015.04.019

No abstract available

PubMed Disclaimer

Comment on

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Baron B, Hirmand M, Smith MR. Tombal B, et al. Eur Urol. 2015 Nov;68(5):787-94. doi: 10.1016/j.eururo.2015.01.027. Epub 2015 Feb 14. Eur Urol. 2015. PMID: 25687533 Clinical Trial.
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI. Higano CS, et al. Eur Urol. 2015 Nov;68(5):795-801. doi: 10.1016/j.eururo.2015.01.026. Epub 2015 Feb 16. Eur Urol. 2015. PMID: 25698064 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information